Molbio Diagnostics IPO Rallies! Grey Market Hits 17% Premium, Analysts Back Investment in Molecular Tech Boom
The Molbio Diagnostics Initial Public Offering (IPO) has witnessed robust investor interest entering its second day of bidding. The company, a leader in point-of-care molecular diagnostics, is currently commanding significant market sentiment as the grey market sends a strong positive signal ahead of listing. The IPO commands a 17% premium in the grey market (GMP), up from 15% on the previous day, suggesting high expectations for its debut performance.Molbio Diagnostics IPO GMP Signals Strong Market Appetite
The current grey market assessment indicates exceptional investor enthusiasm for the company. At the prevailing GMP, which translates to a premium of nearly 15%, the estimated listing price stands around Rs 929 per share. This reflects a strong underlying demand for the diagnostics sector. It is important however that investors view the GMP as an unofficial indicator and not a guarantee of potential gains.The IPO was priced within a band of Rs 768 to Rs 807 per share. At the upper end of this price band, the offering is expected to raise approximately Rs 939.70 crore. The offer structure includes a fresh issue component worth Rs 200 crore and an Offer For Sale (OFS) segment valued at Rs 739.70 crore.
Subscription Data Unveiled for Molbio Diagnostics IPO
The initial day saw steady participation across investor categories, with the overall subscription rate hitting 83%. The IPO offers a substantial pool of 81.58 lakh shares to potential bidders. Retail investors (RIIs) showed sustained interest, subscribing to 77% of their reserved quota of 40.69 lakh shares.Non-Institutional Investors (NIIs) also committed strongly, reaching a subscription rate of 73% against the allocated 17.43 lakh shares. Qualified Institutional Buyers (QIBs), meanwhile, fully subscribed to their allotment, demonstrating high confidence in the company's future prospects.
Strategic Use of IPO Proceeds and Company Background
The capital raised through this public issue will be strategically utilized for significant capacity expansion and infrastructure fortification at Molbio Diagnostics. Roughly Rs 125.12 crore is earmarked for essential capital expenditure to develop a research and development facility, including a Centre of Excellence and related office infrastructure. Furthermore, another Rs 80.81 crore will be used to procure plant and machinery for its manufacturing facilities located in Goa and Visakhapatnam.Established in October 2000, Molbio Diagnostics Ltd. is recognized globally as a molecular diagnostics company. The firm specializes in developing and commercializing rapid diagnostic solutions for both infectious and non-communicable diseases. It is particularly known for its proprietary Truenat platform, a portable PCR-based system designed to deliver accurate results within an hour even in resource-constrained settings.
Financial Health and Expert Investment Verdict
Molbio Diagnostics has demonstrated considerable financial resilience leading up to the public offering. In FY26, the company reported total income increasing 42% year-on-year, reaching Rs 1,455 crore from Rs 1,027 crore in FY25. Profit after tax (PAT) also saw a healthy increase of 18%, climbing to Rs 164 crore.Market analysts concur that the valuations presented in this IPO are reasonable when benchmarked against industry standards. Swastika Research has recommended subscribing, noting that the issue is priced below the average P/E multiple of 64.9 times for listed peers. The firm asserts that Molbio's strong market position and scalable business model provide a solid long-term investment case.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.